Inhibitors of growth factor signalling

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Trastuzumab's success in erbB2-overexpressing breast cancer validates targeted therapy.
• Epidermal growth factor receptor (EGFR) and other ErbB family kinases are frequently overexpressed in solid tumors.
• Targeting tyrosine kinase (TK) activity is a key strategy in cancer drug discovery.

Purpose of the Study:

• To explore novel small molecule inhibitors targeting the EGFR tyrosine kinase.
• To identify and evaluate new drug candidates for breast cancer therapy based on molecular targets.
• To investigate ErbB-associated signaling networks and downstream targets for therapeutic intervention.

Main Methods:

• Development of anilinoquinazoline class inhibitors targeting EGFR tyrosine kinase.
• Evaluation of small molecule inhibitors in preclinical and clinical settings.
• Identification of downstream targets like Ras, MEK, and Src kinase for drug development.

Main Results:

• Anilinoquinazoline inhibitors (e.g., gefitinib, erlotinib) are under evaluation for breast cancer.
• Prenylation inhibitor AZD3409 and Src kinase inhibitor AZD0530 have entered Phase I clinical trials.
• These novel agents target key pathways involved in cell division, motility, and invasiveness.

Conclusions:

• Targeted inhibition of specific signaling pathways is a viable approach to cancer treatment.
• New generations of targeted therapies are emerging for breast cancer, addressing diverse molecular mechanisms.
• Ongoing research into ErbB-associated signaling networks promises further advancements in personalized cancer therapy.